CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-09-30 | ARMISTICE CAPITAL, LLC 10% owner | Purchase | +1,600,376 | $0.33 | $528K | 24,000,000 |
| 2019-09-30 | ARMISTICE CAPITAL, LLC 10% owner | Purchase | +0 | 24,000,000 | ||
| 2019-09-27 | ARMISTICE CAPITAL, LLC 10% owner | Purchase | +972,643 | $0.29 | $282K | 22,399,624 |
| 2019-09-27 | ARMISTICE CAPITAL, LLC 10% owner | Purchase | +0 | 22,399,624 | ||
| 2019-09-26 | ARMISTICE CAPITAL, LLC 10% owner | Purchase | +4,760,314 | $0.28 | $1.3M | 21,426,981 |
| 2019-09-26 | ARMISTICE CAPITAL, LLC 10% owner | Purchase | +0 | 21,426,981 | ||
| 2019-06-12 | VANLENT ANNE Director | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2019-06-12 | VANLENT ANNE Director | Grant or award · Stock Option (right to buy) | +12,700 | 12,700 | ||
| 2019-06-12 | Markham Richard J Director | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2019-06-12 | Markham Richard J Director | Grant or award · Stock Option (right to buy) | +12,700 | 12,700 | ||
| 2019-06-12 | Finney Michael J. Director | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2019-06-12 | Finney Michael J. Director | Grant or award · Stock Option (right to buy) | +12,700 | 12,700 | ||
| 2019-06-12 | COX GEOFFREY F Director | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2019-06-12 | COX GEOFFREY F Director | Grant or award · Stock Option (right to buy) | +12,700 | 12,700 | ||
| 2019-06-12 | Richard John P Director | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2019-06-12 | Richard John P Director | Grant or award · Stock Option (right to buy) | +12,700 | 12,700 | ||
| 2019-05-12 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +124,061 | 124,061 | ||
| 2019-05-12 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +363,261 | 363,261 | ||
| 2019-05-12 | Echerd Margaret VP, Corporate Controller, PAO | Grant or award · Stock Option (right to buy) | +70,444 | 70,444 | ||
| 2019-04-11 | Tucker Sean Chief Scientific Officer | Purchase | +27,273 | $1.10 | $30K | 52,661 |
Page 19 of 23 · 442 trades